Alternatives to raloxifene
1 same-class SPL records vs raloxifene - uses, FAERS reaction fields, and OTC/Rx flags from public FDA sources.
Brand: Evista
About raloxifene
Raloxifene (Evista) is a medicine that can help treat and prevent bone loss (osteoporosis) in women after menopause. It can also lower the chance of getting a certain type of breast cancer.
Used for: This medicine is used to treat and prevent osteoporosis in women after menopause. It can also lower the risk of invasive breast cancer in women after menopause who have osteoporosis or are at high risk of getting it. This medicine is not for treating breast cancer, lowering the risk of breast cancer coming back, or lowering the risk of non-invasive breast cancer.
1 Selective Estrogen Receptor Modulator (SERM) peers (wide set)
raloxifene vs tamoxifen · FAERS reaction fields
FAERS top-reaction field "Fatigue" shows the widest count spread between raloxifene and tamoxifen in this extract (143-report gap on that field). Counts are exposure-weighted submissions, not prevalence rates.
| Side Effect | raloxifene | tamoxifen |
|---|---|---|
| Fatigue | 143 | - |
| Arthralgia | 109 | - |
| Diarrhoea | 109 | - |
| Fall | 107 | - |
| Nausea | 106 | - |
| Headache | 97 | 199 |
| Dizziness | 88 | - |
| Pain | 85 | 243 |
"-" means no reports for that reaction. Report counts reflect total FAERS submissions, not prevalence rates.
raloxifene peer mix vs class inventory
Peer mix
0 OTC and 1 Rx SPL records in this peer set (1 total). Class inventory for Selective Estrogen Receptor Modulator (SERM): 2 drugs.
Frequently Asked Questions
What same-class SPL records sit beside raloxifene? ▼
Reading a wide Selective Estrogen Receptor Modulator (SERM) peer set (1 records)
raloxifene (Evista) sits in a wide Selective Estrogen Receptor Modulator (SERM) peer set (1 of 1 class peers shown). Labeled indication field for raloxifene: This medicine is used to treat and prevent osteoporosis in women after menopause.
Top FAERS reaction fields for raloxifene total 1,006 reports across 10 reactions, set beside tamoxifen. Counts are exposure-weighted submissions, not per-patient risk.
Registry note: Therapeutic-class peer lists are registry indexes, not prescribing advice. This information is for educational purposes only and is not a substitute for professional medical advice. Do not stop or change your medication without talking to your doctor or pharmacist.
Field note for raloxifene: see also the generic vs brand label guide when reading Evista SPL strings.
Read our methodology - how this data is sourced, computed, and verified.